Metacel Pharmaceuticals' Ozobax (baclofen) Receives the US FDA's Approval for Spasticity Due to Multiple Sclerosis
Shots:
- Ozabax is a gamma-aminobutyric acid (GABA-ergic) agonist orally administered low dosage and is available as a 5mg/5 ml oral solution
- The efficacy of Ozobax is based on the bioavailability study evaluated in healthy adults in comparison with Baclofen oral tablets
- Metacel is also planning to launch Ozobax with pending plans. Ozobax has a warning of for its withdrawal can lead to neonatal withdrawal symptoms- drowsiness and sedation- poor tolerability in stroke patients- schizophrenia- or confusional states- and ovarian cysts
Click here to read full press release/ article | Ref: OptumRx | Image: Twitter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
